The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Relapses in multiple sclerosis are age- and time-dependent
Abstract
OBJECTIVES: To examine the relative relapse-rate patterns over time in a relapsing multiple sclerosis (MS) cohort and to investigate potential predictors of relapse rates and periods of low-relapse activity. METHODS: This retrospective cohort study followed 2477 relapsing-remitting (RR) MS patients from onset to 1 July 2003. Annualised relapse rates were examined according to sex, age at onset, the patient's current age and disease duration. The relationship between relapse rates and baseline characteristics (sex, onset age and onset symptoms) were examined using Poisson regression. Time to the first 5 years relapse-free was examined using Kaplan-Meier survival analysis. RESULTS: The mean follow-up time (from onset of MS symptoms) was 20.6 years, during which time 11,722 post-onset relapses were recorded. The relapse rate decreased by 17% every 5 years (between years 5 to 30 post-onset), but this decline increased in magnitude with increasing onset age. Women and those with onset sensory symptoms exhibited a higher relapse rate (p< or =0.001). More than three-quarters of patients (1692/2189) experienced a 5-year relapse-free period during the RR phase. CONCLUSION: Relapse rates were age- and time-dependent. Our observations have clinical implications: 1) any drug able to modify relapse rates has the greatest potential for a population impact in patients <40 years old and within the first few demi-decades of disease; 2) continuation of drug beyond these times may be of limited value; 3) long-term follow-up studies must consider that relapse rates probably decline at different rates over time according to the patient's onset age; 4) a relapse-quiescent period in MS is not uncommon.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2005) · Statistics for Biology and Health · doi:10.1007/0-387-27255-0_9 · Cited by 20,133
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Models for Longitudinal Data: A Generalized Estimating Equation Approach
Zeger, S. L., Liang, K.-Y., & Albert, P. S. (1988) · Biometrics · doi:10.2307/2531734 · Cited by 4,505
Natural history of multiple sclerosis: a unifying concept
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awl007 · Cited by 905
(2006) · Elsevier eBooks · doi:10.1016/b978-0-443-07271-0.x5001-0 · Cited by 769
Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results
Li, D. K. B., Zhao, G. J., Paty, D. W., & the University of British Columbia MS/MRI Analysis Research Group and the SPECTRIMS Study Group* (2001) · Neurology · doi:10.1212/wnl.56.11.1505 · Cited by 458
Effect of relapses on development of residual deficit in multiple sclerosis
Lublin, F. D., Baier, M., & Cutter, G. (2003) · Neurology · doi:10.1212/01.wnl.0000096175.39831.21 · Cited by 421
Disability progression in multiple sclerosis is slower than previously reported
Tremlett, H., Paty, D., & Devonshire, V. (2006) · Neurology · doi:10.1212/01.wnl.0000194259.90286.fe · Cited by 343
Self-citationThe Natural History of Multiple Sclerosis
Weinshenker, B. G. (1995) · Neurologic Clinics · doi:10.1016/s0733-8619(18)30064-1 · Cited by 313
Some Aspects of the Natural History of Disseminated Sclerosis
(2015) · QJM: An International Journal of Medicine · doi:10.1093/qjmed/21.2.135 · Cited by 237
Natural history of secondary-progressive multiple sclerosis
Tremlett, H., Zhao, Y., & Devonshire, V. (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458507084264 · Cited by 217
Self-citationChange in MS-related disability in a population-based cohort: A 10-year follow-up study
Pittock, S. J., Mayr, W. T., McClelland, R. L., Jorgensen, N. W., Weigand, S. D., Noseworthy, J. H., Weinshenker, B. G., & Rodriguez, M. (2004) · Neurology · doi:10.1212/01.wnl.0000101724.93433.00 · Cited by 160
Life expectancy in patients attending multiple sclerosis clinics
Sadovnick, A. D., Ebers, G. C., Wilson, R. W., & Paty, D. W. (1992) · Neurology · doi:10.1212/wnl.42.5.991 · Cited by 159
The natural history of relapses in multiple sclerosis
Vollmer, T. L. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.01.065 · Cited by 140
Biomarkers and surrogate outcomes in neurodegenerative disease: Lessons from multiple sclerosis
Miller, D. H. (2004) · NeuroRx · doi:10.1602/neurorx.1.2.284 · Cited by 138
Is late-onset multiple sclerosis associated with a worse outcome?
Tremlett, H. L., & Devonshire, V. A. (2006) · Neurology · doi:10.1212/01.wnl.0000237475.01655.9d · Cited by 136
Self-citationPatzold, U., & Pocklington, P. R. (1982) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1982.tb03084.x · Cited by 121
Growth Hormone and Glucose Homeostasis
Jørgensen, J. O. L., Krag, M. B., Jessen, N., Nørrelund, H., Vestergaard, E. T., Møller, N., & Christiansen, J. S. (2004) · Hormone Research in Paediatrics · doi:10.1159/000080499 · Cited by 108
The natural history of primary progressive MS in British Columbia, Canada
Tremlett, H. L., Paty, D. W., & Devonshire, V. A. (2005) · Neurology · doi:10.1212/01.wnl.0000188880.17038.1d · Cited by 102
Self-citationPrevalence of Multiple Sclerosis in British Columbia
Sweeney, V. P., Sadovnick, A. D., & Brandejs, V. (1986) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100035782 · Cited by 98
Goodkin, D. E. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520460093019 · Cited by 90
Liu, C., & Blumhardt, L. D. (2000) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.4.450 · Cited by 86
Clinical studies on multiple sclerosis
Broman, T., Andersen, O., & Bergmann, L. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1981.tb00745.x · Cited by 84
Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis
Tortorella, C., Bellacosa, A., Paolicelli, D., Fuiani, A., Monte, E. D., Simone, I. L., Giaquinto, P., Livrea, P., & Trojano, M. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.08.006 · Cited by 74
The course of multiple sclerosis in 73 cases with computer-designed curves.
Fog, T., & Linnemann, F. (1970) · PubMed · Cited by 73
The psychosocial effect of multiple sclerosis: The impact of relapses
Halper, J. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.01.059 · Cited by 66
Digre, K. B. (2002) · Journal of Neuro-Ophthalmology · doi:10.1097/00041327-200206000-00041 · Cited by 19
Cited by
Androgen-Induced Immunosuppression
Gubbels Bupp, M. R., & Jorgensen, T. N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00794 · Cited by 390
Treatment of Neuromyelitis Optica With Mycophenolate Mofetil: Retrospective Analysis of 24 Patients
Jacob, A., Matiello, M., Weinshenker, B. G., Wingerchuk, D. M., Lucchinetti, C., Shuster, E., Carter, J., Keegan, B. M., Kantarci, O. H., & Pittock, S. J. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.175 · Cited by 308
Epidemiology and treatment of multiple sclerosis in elderly populations
Vaughn, C. B., Jakimovski, D., Kavak, K. S., Ramanathan, M., Benedict, R. H. B., Zivadinov, R., & Weinstock-Guttman, B. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0183-3 · Cited by 306
Shirani, A., Zhao, Y., Karim, M. E., Evans, C., Kingwell, E., van der Kop, M. L., Oger, J., Gustafson, P., Petkau, J., & Tremlett, H. (2012) · JAMA · doi:10.1001/jama.2012.7625 · Cited by 263
Self-citationNew perspectives in the natural history of multiple sclerosis
Tremlett, H., Zhao, Y., Rieckmann, P., & Hutchinson, M. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e3973f · Cited by 261
Self-citation
Metadata
- Authors
- Tremlett, H., Zhao, Y., Joseph, J., Devonshire, V, & Neurologists*, T. U. C.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2008-12-01
- Volume
- 79
- Issue
- 12
- Pages
- 1368-1374
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2146236437
- Cited by
- 277
- References
- 28
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.